| 
			  
			
			
 
  by Frank Pajonk, M.D., Ph.D.
 February 14, 
			2012
 from 
			UCLA-JonssonComprehensiveCancerCenter 
			Website
 
			  
			  
			Breast cancer stem cells 
			are thought to be the sole source of tumor recurrence and are known 
			to be resistant to radiation therapy and don’t respond well to 
			chemotherapy.
 Now, researchers with the UCLA Department of Radiation Oncology at 
			UCLA’s Jonsson Comprehensive Cancer Center report for the first time 
			that radiation treatment - despite killing half of all tumor cells 
			during every treatment - transforms other cancer cells into 
			treatment-resistant breast cancer stem cells.
 
 The generation of these breast cancer stem cells counteracts the 
			otherwise highly efficient radiation treatment.
 
			  
			If scientists can 
			uncover the mechanisms and prevent this transformation from 
			occurring, radiation treatment for breast cancer could become even 
			more effective, said study senior author Dr. Frank Pajonk, an 
			associate professor of radiation oncology and Jonsson Cancer Center 
			researcher. 
				
				“We found that these 
				induced breast cancer stem cells (iBCSC) were generated by 
				radiation-induced activation of the same cellular pathways used 
				to reprogram normal cells into induced pluripotent stem cells (iPS) 
				in regenerative medicine,” said Pajonk, who also is a scientist 
				with the Eli and Edythe Broad Center of Regenerative Medicine at 
				UCLA.    
				“It was remarkable 
				that these breast cancers used the same reprogramming pathways 
				to fight back against the radiation treatment.” 
			The study appears Feb. 
			13, 2012 in the early online edition of the peer-reviewed journal 
			Stem Cells. 
				
				“Controlling the 
				radiation resistance of breast cancer stem cells and the 
				generation of new iBCSC during radiation treatment may 
				ultimately improve curability and may allow for de-escalation of 
				the total radiation doses currently given to breast cancer 
				patients, thereby reducing acute and long-term adverse effects,” 
				the study states. 
			There are very few 
			breast cancer stem cells in a larger pool of breast cancer cells.
			 
			  
			In this study, Pajonk 
			and his team eliminated the smaller pool of breast cancer stem cells 
			and then irradiated the remaining breast cancer cells and placed 
			them into mice.
 Using a unique imaging system that Pajonk and his team developed to 
			visualize cancer stem cells, the researchers were able to observe 
			their initial generation into iBCSC in response to the radiation 
			treatment.
 
			  
			The newly generated 
			iBCSC were remarkably similar to breast cancer stem cells found in 
			tumors that had not been irradiated, Pajonk said.
 The team also found that the iBCSC had a more than 30-fold 
			increased ability to form tumors compared to the 
			non-irradiated breast cancer cells from which they originated.
 
 Pajonk said that the study unites the competing models of clonal 
			evolution and the hierarchical organization of breast cancers, as it 
			suggests that undisturbed, growing tumors maintain a small number of 
			cancer stem cells.
 
			  
			However, if challenged 
			by various stressors that threaten their numbers, including ionizing 
			radiation, the breast cancer cells generate iBCSC that may, together 
			with the surviving cancer stem cells, repopulate the tumor. 
				
				“What is really 
				exciting about this study is that it gives us a much more 
				complex understanding of the interaction of radiation with 
				cancer cells that goes far beyond DNA damage and cell killing,” 
				Pajonk said.   
				“The study may carry 
				enormous potential to make radiation even better.” 
			Pajonk stressed that 
			breast cancer patients should not be alarmed by the study findings 
			and should continue to undergo radiation if recommended by their 
			oncologists. 
				
				“Radiation is an 
				extremely powerful tool in the fight against breast cancer,” he 
				said. “If we can uncover the mechanism driving this 
				transformation, we may be able to stop it and make the therapy 
				even more powerful.” 
			This study was funded 
			by, 
				
					
					
					the National 
					Cancer Institute
					
					the California 
					Breast Cancer Research Program 
					
					the Department 
					of Defense 
			UCLA's Jonsson 
			Comprehensive Cancer Center has more than 240 researchers and 
			clinicians engaged in disease research, prevention, detection, 
			control, treatment and education.  
			  
			One of the nation's 
			largest comprehensive cancer centers, the Jonsson center is 
			dedicated to promoting research and translating basic science into 
			leading-edge clinical studies.  
			  
			In July 2011, the 
			Jonsson Cancer Center was named among the top 10 cancer centers 
			nationwide by U.S. News & World Report, a ranking it has held for 11 
			of the last 12 years.
 
			  |